-
The rate is much lower with HR+/HER2− metastatic breast cancer.
-
New guidelines from the European Association of Neuro-Oncology.
-
Radiotherapy outcomes differ by molecular subgroup.
Topical minoxidil is beneficial.
The rate is much lower with HR+/HER2− metastatic breast cancer.
New guidelines from the European Association of Neuro-Oncology.
Radiotherapy outcomes differ by molecular subgroup.
Topical minoxidil is beneficial.
Phase 3 NALA is for patients previously treated with at least 2 HER2-directed regimens.
Intraventricular methotrexate can improve poor outcomes with systemic chemotherapy alone.
Diagnosis, treatment, funding are all greatly affected.
The treatment will be available under the Cancer Drugs Fund
Physicians are again discussing hospice care with patients.
This response rate is more than double that in the phase 2 HER2CLIMB study.
Rapid, durable responses seen especially in high-grade gliomas.
The treatment is available through the Cancer Drugs Fund
Adjusting for site and stage eliminate the link between chemotherapy and stroke.
The test identifies tissue of origin too.
Cancer patients may be at high risk for complications, especially those with lymphopenia, neutropenia.
Findings from Wuhan, China, suggest aggressive measures to curtail frequency of hospital visits.
Findings from a prospective study of UK participants.